Tremelimumab,Durvalumab 
astrazeneca
[]
infinity neoadjuvant io with durvalumab + priming tremelimumab for esophageal cancer is promising for t1/t2! t4 clearly different... perhaps need more io treatment vs aggressive biology. #gi23 
GI Oncologist at @IUCancerCenter. @uw_hemeoncpc and @UChicagomed alum. Tweets are my own.